BioSpace News Archive

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”) today announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced positive topline results from the Phase 2a Carpo trial evaluating TP-05, a novel, investigational oral therapeutic for the prevention of Lyme disease.

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported net revenue growth of more than 30% for the fourth quarter and full year ended December 31, 2023.

Ocular Therapeutix, Inc. , today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $325.0 million, before deducting placement agent fees and other offering expenses.

DermBiont announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024.

Daré Bioscience, Inc. today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting.

Motus GI Holdings, Inc. today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock.

Bionano Genomics, Inc., announced that optical genome mapping was included for the first time in the American College of Medical Genetics and Genomics technical laboratory standards documentation for solid tumor analysis.

Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.